Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Juvisy sur Orge, France Clinical Trials

A listing of Juvisy sur Orge, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (33) clinical trials

A Randomized Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis

NUMBER OF PATIENTS : 75 patients in each group i.e. a total of 150 patients. RECRUITMENT PERIOD : 24 months STUDY DURATION : 36 months PRIMARY END POINT : Treatment failure is defined by: Absence of steroid-free remission at W52 according to the total Mayo Disease Activity Index score OR ...

Phase

8.21 miles

Learn More »

Desensitization With Bortezomib Before a Living Kidney Donation

The investigators plan to study the role of bortezomib for desensitizing patients awaiting a living kidney donation who have a titer of Donor Specific anti HLA Antibody (DSA) between 1000 and 3000 MFI with a multicentre pilot study of 10 patients. The effect of bortezomib will be observed up to ...

Phase

8.4 miles

Learn More »

TICON-Day 3 Time Lapse Versus Conventional Method in Day 3 Embryo Culture and Assessment

The main purpose of the study is to evaluate the overall clinical value of GERI+ as an integrated embryo culture and assessment system, providing an undisturbed culture environment, continuous monitoring of embryo development and automated scoring using a predictive algorithm.

Phase

8.77 miles

Learn More »

Effect of Adaptive Servo Ventilation (ASV) on Survival and Hospital Admissions in Heart Failure

Sleep Apnea (SA) is a disorder that causes pauses in breathing during sleep that expose the heart to oxygen deprivation. It is common in patients with heart failure (HF) where it is associated with increased risk of hospitalizations and death. It is not known however whether treating SA reduces these ...

Phase

9.12 miles

Learn More »

Study of the Effects on Motor Recovery of Early Post-stroke Spasticity Treatment

Background: Stroke is the first cause of motor impairment and disability in adults. 80% of post-stroke survivors have a motor weakness resulting in hemiplegia. Post-stroke patients partially recover from their motor impairments . These patients reach their maximum motor score round the first 20 weeks. In all cases, motor recovery ...

Phase

9.62 miles

Learn More »

Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis

The study duration per patient is expected to be approximately 32 weeks, with up to 4-week screening, 24 weeks treatment, and 2-4 weeks post-treatment observations.

Phase

9.62 miles

Learn More »

Randomized Comparison of Cangrelor Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.

Primary percutaneous coronary intervention (PCI) is the main reperfusion therapy in patients with ST-elevation myocardial infarction (STEMI). Ancillary pharmacological therapy includes dual antiplatelet therapy with aspirin and an inhibitor of P2Y12 receptor, responsible of adenosine diphosphate(ADP)-mediated platelet activation.Prasugrel and ticagrelor are the most recent and efficient oral P2Y12 inhibitors available ...

Phase

9.62 miles

Learn More »

Blood Pressure Reduction to Limit the Evolution of Vascular Brain Lesions in Elderly Individuals

SCIENTIFIC BACKGROUND: White Matter Lesions (WML) are cerebrovascular abnormalities discovered on MRI that are associated with an increased risk of dementia. High blood pressure (BP) is a major risk factor for WML. WML are therefore key lesions in the causal chain linking vascular factors and dementia, particularly Alzheimer's disease. However, ...

Phase

9.62 miles

Learn More »

Multicenter Randomized Prospective Trial Comparing Methotrexate Alone or in Combination With Adalimumab in Early Arthritis

Patients: early ( less than 6 months), active ( DAS>5.2),potentially severe ( Leiden score>6) Study design:12 months, prospective , randomized, open Study treatments: Methotrexate at a weekly dose of 0.3mg/kilo alone or in combination with adalimumab 40 mg every the other week Outcome measures: DAS over the 12 months

Phase

9.88 miles

Learn More »

Oral Anticoagulation in Haemodialysis Patients

Guidelines recommend oral anticoagulation with vitamin K antagonists for atrial fibrillation whenever the CHADS2VASC score is superior or equal to 2. As there are no specific guidelines for the hemodialysis patients with atrial fibrillation, the general guidelines apply. However, several retrospective studies suggest that these patients do not benefit from ...

Phase

9.88 miles

Learn More »